urovestВестник урологииUrology Herald2308-6424Rostov State Medical University10.21886/2308-6424-2022-10-3-151-155urovest-591Research ArticleОБЗОРЫ ПУБЛИКАЦИЙ – ТЕКУЩЕЕ МНЕНИЕCURRENT STATE-OF-THE-ARTНовые варианты лечения пациентов с раком мочевого пузыря: по материалам конгресса ASCO 2022 и не толькоNew treatment options for bladder cancer patients: based on ASCO 2022 materials and beyondhttps://orcid.org/0000-0003-2587-0902ЗятчинИ. В.ZyatchinI. V.

Илья Владиславович Зятчин — клинический ординатор кафедры урологии с курсом урологии с клиникой

197022, Россия, г. Санкт-Петербург, ул. Льва Толстого, д. 6–8

Ilya V. Zyatchin — Resident, Dept. of Urology with a Course of Clinical Urology

6–8 Lev Tolstoy St., St. Petersburg 197022, Russian Federation

ily6102@yandex.ruhttps://orcid.org/0000-0001-5183-5153РеваС. А.RevaS. A.

Сергей Александрович Рева — кандидат медицинских наук; заведующий онкологическим отделением №6 (андрологии и онкоурологии) НИЦ урологии

197022, Россия, г. Санкт-Петербург, ул. Льва Толстого, д. 6–8

197758, Россия, г. Санкт-Петербург, пос. Песочный, ул. Ленинградская, д. 68

Sergey A. Reva — M.D., Cand.Sc.(Med); Head, Oncology Division No. 6 (Andrology and Oncological Urology), Research Center of Urology; Researcher

6–8 Lev Tolstoy St., St. Petersburg 197022, Russian Federation

68 Leningradskaya St., Pesochnyy, St. Petersburg, 197758, Russian Federation

sgreva79@mail.ruФГБОУ ВО «Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова» Минздрава РоссииРоссияPavlov First Saint-Petersburg State Medical University (Pavlov University)Russian FederationФГБОУ ВО «Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова» Минздрава России; ФГБУ «Национальный медицинский исследовательский центр онкологии имени Н.Н. Петрова» Минздрава РоссииРоссияPavlov First Saint-Petersburg State Medical University (Pavlov University); Petrov National Medical Research Center of OncologyRussian Federation202201102022103151155Copyright © Зятчин И.В., Рева С.А., 20222022Зятчин И.В., Рева С.А.Zyatchin I.V., Reva S.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.urovest.ru/jour/article/view/591

Рак мочевого пузыря занимает 4-е место по распространённости среди онкологических заболеваний, а также 8-е место по частоте причин смерти от рака у мужчин. Появление новых системных методов лечения, в том числе ингибиторов PD-1 и PD-L1, и прогресс в разработке биомаркеров произвели революцию в лечении данного заболевания. Текущие рекомендации Национальной всеобщей онкологической сети (National Comprehensive Cancer Network, NCCN) поддерживают включение некоторых из новых терапевтических средств в клиническую практику. За последнее десятилетие получено большое количество разрешений для иммуно-терапевтических средств. В связи с тем, что рак мочевого пузыря характеризуется высокой частотой мутаций, имело место широкое внедрение препаратов группы ингибиторов иммунных контрольных точек. Все исследования этого обзора представлены на недавнем конгрессе Американского общества клинических онкологов (American Society of Clinical Oncology, ASCO) и опубликованы в крупнейших периодических изданиях.

Bladder cancer is the fourth most common cancer worldwide and the eighth leading cause of cancer mortality in men. The advent of new systemic therapies, including PD-1 and PD-L1 inhibitors, and advances in biomarker development have revolutionized the treatment of this disease. The current guidelines of the National Comprehensive Cancer Network (NCCN) support the inclusion of some new therapies in clinical practice. Over the past decade, many approvals for immuno-therapeutic agents have been obtained. Since bladder cancer is characterized by a high frequency of mutations, there has been a widespread introduction of medicines from the group of immune checkpoint inhibitors. All studies from this review were presented at a recent meeting of the American Society of Clinical Oncology (ASCO) and published in reputable journals.

рак мочевого пузыряингибиторы иммунных контрольных точектаргетная терапияхимиотерапияконъюгаты антитело-препаратbladder cancerimmune checkpoint inhibitorstargeted therapychemotherapyantibody-drug conjugatesReferencesFlaig TW, Spiess PE, Abern M, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Chan K, Chang S, Friedlander T, Greenberg RE, Guru KA, Herr HW, Hoffman-Censits J, Kishan A, Kundu S, Lele SM, Mamtani R, Margulis V, Mian OY, Michalski J, Montgomery JS, Nandagopal L, Pagliaro LC, Parikh M, Patterson A, Plimack ER, Pohar KS, Preston MA, Richards K, Sexton WJ, Siefker-Radtke AO, Tollefson M, Tward J, Wright JL, Dwyer MA, Cassara CJ, Gurski LA. NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022. J Natl Compr Canc Netw. 2022;20(8):866-878. https://doi.org/10.6004/jnccn.2022.0041Flaig TW, Spiess PE, Abern M, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Chan K, Chang S, Friedlander T, Greenberg RE, Guru KA, Herr HW, Hoffman-Censits J, Kishan A, Kundu S, Lele SM, Mamtani R, Margulis V, Mian OY, Michalski J, Montgomery JS, Nandagopal L, Pagliaro LC, Parikh M, Patterson A, Plimack ER, Pohar KS, Preston MA, Richards K, Sexton WJ, Siefker-Radtke AO, Tollefson M, Tward J, Wright JL, Dwyer MA, Cassara CJ, Gurski LA. NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022. J Natl Compr Canc Netw. 2022;20(8):866-878. https://doi.org/10.6004/jnccn.2022.0041Steinberg RL, Thomas LJ, Brooks N, Mott SL, Vitale A, Crump T, Rao MY, Daniels MJ, Wang J, Nagaraju S, DeWolf WC, Lamm DL, Kates M, Hyndman ME, Kamat AM, Bivalacqua TJ, Nepple KG, O'Donnell MA. Multi-Institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy for Nonmuscle Invasive Bladder Cancer. J Urol. 2020;203(5):902-909. https://doi.org/10.1097/JU.0000000000000688Steinberg RL, Thomas LJ, Brooks N, Mott SL, Vitale A, Crump T, Rao MY, Daniels MJ, Wang J, Nagaraju S, DeWolf WC, Lamm DL, Kates M, Hyndman ME, Kamat AM, Bivalacqua TJ, Nepple KG, O'Donnell MA. Multi-Institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy for Nonmuscle Invasive Bladder Cancer. J Urol. 2020;203(5):902-909. https://doi.org/10.1097/JU.0000000000000688Balar AV, Kamat AM, Kulkarni GS, Uchio EM, Boormans JL, Roumiguié M, Krieger LEM, Singer EA, Bajorin DF, Grivas P, Seo HK, Nishiyama H, Konety BR, Li H, Nam K, Kapadia E, Frenkl T, de Wit R. Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study. Lancet Oncol. 2021;22(7):919-930. https://doi.org/10.1016/S1470-2045(21)00147-9Balar AV, Kamat AM, Kulkarni GS, Uchio EM, Boormans JL, Roumiguié M, Krieger LEM, Singer EA, Bajorin DF, Grivas P, Seo HK, Nishiyama H, Konety BR, Li H, Nam K, Kapadia E, Frenkl T, de Wit R. Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study. Lancet Oncol. 2021;22(7):919-930. https://doi.org/10.1016/S1470-2045(21)00147-9Bajorin DF, Witjes JA, Gschwend JE, Schenker M, Valderrama BP, Tomita Y, Bamias A, Lebret T, Shariat SF, Park SH, Ye D, Agerbaek M, Enting D, McDermott R, Gajate P, Peer A, Milowsky MI, Nosov A, Neif Antonio J Jr, Tupikowski K, Toms L, Fischer BS, Qureshi A, Collette S, Unsal-Kacmaz K, Broughton E, Zardavas D, Koon HB, Galsky MD. Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma. N Engl J Med. 2021;384(22):2102-2114. https://doi.org/10.1056/NEJMoa2034442Bajorin DF, Witjes JA, Gschwend JE, Schenker M, Valderrama BP, Tomita Y, Bamias A, Lebret T, Shariat SF, Park SH, Ye D, Agerbaek M, Enting D, McDermott R, Gajate P, Peer A, Milowsky MI, Nosov A, Neif Antonio J Jr, Tupikowski K, Toms L, Fischer BS, Qureshi A, Collette S, Unsal-Kacmaz K, Broughton E, Zardavas D, Koon HB, Galsky MD. Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma. N Engl J Med. 2021;384(22):2102-2114. https://doi.org/10.1056/NEJMoa2034442Powles T, Park SH, Voog E, Caserta C, Valderrama BP, Gurney H, Kalofonos H, Radulović S, Demey W, Ullén A, Loriot Y, Sridhar SS, Tsuchiya N, Kopyltsov E, Sternberg CN, Bellmunt J, Aragon-Ching JB, Petrylak DP, Laliberte R, Wang J, Huang B, Davis C, Fowst C, Costa N, Blake-Haskins JA, di Pietro A, Grivas P. Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma. N Engl J Med. 2020;383(13):1218-1230. https://doi.org/10.1056/NEJMoa2002788Powles T, Park SH, Voog E, Caserta C, Valderrama BP, Gurney H, Kalofonos H, Radulović S, Demey W, Ullén A, Loriot Y, Sridhar SS, Tsuchiya N, Kopyltsov E, Sternberg CN, Bellmunt J, Aragon-Ching JB, Petrylak DP, Laliberte R, Wang J, Huang B, Davis C, Fowst C, Costa N, Blake-Haskins JA, di Pietro A, Grivas P. Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma. N Engl J Med. 2020;383(13):1218-1230. https://doi.org/10.1056/NEJMoa2002788Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, Loriot Y, Necchi A, Hoffman-Censits J, Perez-Gracia JL, Dawson NA, van der Heijden MS, Dreicer R, Srinivas S, Retz MM, Joseph RW, Drakaki A, Vaishampayan UN, Sridhar SS, Quinn DI, Durán I, Shaffer DR, Eigl BJ, Grivas PD, Yu EY, Li S, Kadel EE 3rd, Boyd Z, Bourgon R, Hegde PS, Mariathasan S, Thåström A, Abidoye OO, Fine GD, Bajorin DF; IMvigor210 Study Group. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet. 2017;389(10064):67-76. https://doi.org/10.1016/S0140-6736(16)32455-2Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, Loriot Y, Necchi A, Hoffman-Censits J, Perez-Gracia JL, Dawson NA, van der Heijden MS, Dreicer R, Srinivas S, Retz MM, Joseph RW, Drakaki A, Vaishampayan UN, Sridhar SS, Quinn DI, Durán I, Shaffer DR, Eigl BJ, Grivas PD, Yu EY, Li S, Kadel EE 3rd, Boyd Z, Bourgon R, Hegde PS, Mariathasan S, Thåström A, Abidoye OO, Fine GD, Bajorin DF; IMvigor210 Study Group. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet. 2017;389(10064):67-76. https://doi.org/10.1016/S0140-6736(16)32455-2Powles T, Rosenberg JE, Sonpavde GP, Loriot Y, Durán I, Lee JL, Matsubara N, Vulsteke C, Castellano D, Wu C, Campbell M, Matsangou M, Petrylak DP. Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma. N Engl J Med. 2021;384(12):1125-1135. https://doi.org/10.1056/NEJMoa2035807Powles T, Rosenberg JE, Sonpavde GP, Loriot Y, Durán I, Lee JL, Matsubara N, Vulsteke C, Castellano D, Wu C, Campbell M, Matsangou M, Petrylak DP. Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma. N Engl J Med. 2021;384(12):1125-1135. https://doi.org/10.1056/NEJMoa2035807Tagawa ST, Balar AV, Petrylak DP, Kalebasty AR, Loriot Y, Fléchon A, Jain RK, Agarwal N, Bupathi M, Barthelemy P, Beuzeboc P, Palmbos P, Kyriakopoulos CE, Pouessel D, Sternberg CN, Hong Q, Goswami T, Itri LM, Grivas P. TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors. J Clin Oncol. 2021;39(22):2474-2485. https://doi.org/10.1200/JCO.20.03489Tagawa ST, Balar AV, Petrylak DP, Kalebasty AR, Loriot Y, Fléchon A, Jain RK, Agarwal N, Bupathi M, Barthelemy P, Beuzeboc P, Palmbos P, Kyriakopoulos CE, Pouessel D, Sternberg CN, Hong Q, Goswami T, Itri LM, Grivas P. TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors. J Clin Oncol. 2021;39(22):2474-2485. https://doi.org/10.1200/JCO.20.03489Loriot Y, Necchi A, Park SH, Garcia-Donas J, Huddart R, Burgess E, Fleming M, Rezazadeh A, Mellado B, Varlamov S, Joshi M, Duran I, Tagawa ST, Zakharia Y, Zhong B, Stuyckens K, Santiago-Walker A, De Porre P, O'Hagan A, Avadhani A, Siefker-Radtke AO; BLC2001 Study Group. Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. N Engl J Med. 2019;381(4):338-348. https://doi.org/10.1056/NEJMoa1817323Loriot Y, Necchi A, Park SH, Garcia-Donas J, Huddart R, Burgess E, Fleming M, Rezazadeh A, Mellado B, Varlamov S, Joshi M, Duran I, Tagawa ST, Zakharia Y, Zhong B, Stuyckens K, Santiago-Walker A, De Porre P, O'Hagan A, Avadhani A, Siefker-Radtke AO; BLC2001 Study Group. Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. N Engl J Med. 2019;381(4):338-348. https://doi.org/10.1056/NEJMoa1817323

The authors declare that there are no conflicts of interest present.